Literature DB >> 620915

Effects of renal failure on blood levels of cimetidine.

K W Ma, D C Brown, D S Masler, S E Silvis.   

Abstract

Serial blood samples for determination of drug levels were obtained after intravenous administration of 300 mg of cimetidine. Sixteen patients with varying degrees of renal failure were studied. There was a prolongation of drug half-life in patients with renal insufficiency compared with that in normal controls (P less than 0.001). A significant inverse relationship between the half-life and the creatinine clearance was noted (r= 0.69; P less than 0.01). The effect of hemodialysis was studied in 12 patients. Cimetidine was found to be dialyzable. This was demonstrated both by a shortening of the half-life of the drug during dialysis and by measurement of dialysance. This suggests that the dose schedule should be modified for patients with renal insufficiency and for those on hemodialysis. A single intraveno us dose of cimetidine was well tolerated by the patients. One patient developed an urticarial skin rash, believed to be allergic in nature. There was a transient, mild (but significant) rise in blood urea nitrogen and serum creatinine concentration in 5 patients with moderate renal failure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620915

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

Review 1.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Oral absorption of cimetidine and its clearance in patients with renal failure.

Authors:  R Larsson; G Bodemar; B Norlander
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

4.  Steady-state kinetics and dosage requirements of cimetidine in renal failure.

Authors:  R Larsson; B Norlander; G Bodemar; A Walan
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

5.  Pharmacokinetics of cimetidine after single doses and during continuous treatment.

Authors:  G Bodemar; B Norlander; A Walan
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

6.  Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.

Authors:  T Takabatake; H Ohta; M Maekawa; Y Yamamoto; Y Ishida; H Hara; S Nakamura; Y Ushiogi; M Kawabata; N Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

9.  Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.

Authors:  R Larsson; P Erlanson; G Bodemar; B Norlander; L Fransson; L Strouth
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.

Authors:  R Larsson; P Erlanson; G Bodemar; A Walan; A Bertler; L Fransson; B Norlander
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.